The ADAPT-DES study design has been described in detail previously. 7 Briefly, ADAPT-DES was a prospective, multicenter registry
D
espite their poor mid-and long-term patency rate, saphenous vein grafts (SVG) are still commonly used among patients undergoing coronary artery bypass graft surgery. 1 SVG represents a distinct coronary revascularization conduit entity, with specific pathophysiology and patterns of degeneration and failure. [2] [3] [4] Percutaneous coronary intervention (PCI) of SVGs has historically been associated with higher early and late adverse ischemic event rates compared with PCI of lesions in native coronary arteries. 5, 6 However, there is a paucity of contemporary data on the second-generation drug-eluting stent (DES) use within SVG, and no studies have specifically examined the impact of high platelet reactivity (HPR) on the occurrence of ischemic events after SVG PCI with DES. Therefore, using the large ADAPT-DES study (Assessment of Dual Antiplatelet Therapy With Drug Eluting Stents database, we sought to study the relationship between HPR on dual antiplatelet therapy (DAPT) and the occurrence of ischemic and bleeding adverse events after PCI of SVGs compared with PCI of native coronary lesions.
Methods

Study Protocol
specifically designed to determine the relationship between platelet reactivity and subsequent clinical events after successful PCI with DES. A total of 8582 subjects were prospectively enrolled at 11 sites in the United States and Germany. All subjects who were successfully treated with ≥1 DES and adequately loaded with aspirin and clopidogrel were eligible for enrollment, regardless of patient or lesion complexity. The only major exclusion criteria were the occurrence of a major complication during the procedure or before platelet function testing or if bypass surgery was planned after PCI. Platelet reactivity was assessed using the VerifyNow aspirin, P2Y12, and IIb/ IIIa assays (Accumetrics, San Diego, CA). 7 After PCI, subjects were treated with aspirin indefinitely and clopidogrel was recommended for at least 1 year. All other treatments were as per standard of care. Clinical follow-up was scheduled at 30 days, 1 year, and 2 years. An independent clinical events committee masked to VerifyNow results adjudicated all death, myocardial infarction (MI), and stent thrombosis events using original source documents. The institutional review board at every participating center approved the study, and all eligible subjects signed written informed consent.
Objectives and Definitions
The objectives of the study were to (1) describe the clinical outcomes of patients who underwent PCI of SVG lesions compared with PCI of native coronary artery lesions and (2) assess whether HPR has a greater effect on the risk of adverse events after PCI of SVG than after PCI of a lesion in a native coronary artery.
SVG PCI was defined as any PCI of a lesion within an SVG. HPR on clopidogrel was defined using the discrete cutoff level of VerifyNow P2Y12 reaction units (PRU) >208. Major adverse cardiac events was defined in ADAPT-DES as the composite of cardiac death, MI, or stent thrombosis. 8 Other end points evaluated in the present study included all-cause mortality, cardiac mortality, target vessel failure, ischemia-driven revascularization, and major bleeding. MI was defined according to the Acute Catheterization and Urgent Intervention Triage Strategy criteria (Table I in the Data  Supplement) . 8, 9 Definite or probable stent thrombosis was defined according to the Academic Research Consortium definition. 10 Target vessel failure was defined as the composite of all-cause death, MI, or ischemia-driven target vessel revascularization. Clinically relevant bleeding was defined as the occurrence of any of the following: A thrombolysis in myocardial infarction major or minor bleed, a global use of strategies to open occluded arteries severe or moderate bleed, an acute catheterization and urgent intervention triage strategy major bleed, or any post-discharge bleeding event requiring medical attention.
Statistical Analysis
Patients who underwent SVG PCI were compared with patients who underwent non-SVG PCI. Sensitivity analysis were performed comparing patients with SVG PCI to patients with non-SVG PCI who had previously undergone coronary artery bypass grafting (CABG). Descriptive statistics are presented as mean±SD and were compared with the Student t test; categorical variables are reported as percentages and were tested with the χ 2 test. Event rates during follow-up were estimated by Kaplan-Meier methods. The adjusted association between SVG PCI and PRU was assessed by multivariable linear regression adjusted for age, sex, diabetes mellitus, current smoking status, renal insufficiency, clinical presentation, previous MI, and anemia. Unadjusted and adjusted hazard ratios for 2-year outcomes were determined from Cox proportional hazards models. The multivariable models included age, sex, diabetes mellitus, current smoking, history of renal insufficiency, clinical presentation, previous MI, previous CABG, anemia, PRU, left anterior descending coronary artery as the culprit vessel, multivessel disease, moderate or severe coronary calcification, and total stent length. To avoid model overfitting because of a smaller number of events, multivariable models assessing the effect of SVG PCI on the risk of stent thrombosis were adjusted for age, diabetes mellitus, previous CABG, current smoking, clinical presentation, PRU, multivessel disease, and total stent length. The consistency of the effect of SVG PCI according to HPR (no HPR versus HPR) was evaluated by inclusion of an interaction term in the Cox proportional hazards model. A sensitivity analysis was performed, which tested for an interaction between SVG and non-SVG PCI and platelet reactivity entered as a continuous linear variable. We also tested for an interaction between SVG and non-SVG PCI and clinical presentation.
Sensitivity analyses using multivariable adjustment and propensity score matching were used to compare SVG PCI with non-SVG PCI among patients with previous CABG. The following variables were included in the propensity score model: age, sex, diabetes mellitus, current smoking, renal insufficiency, clinical presentation, previous MI, previous CABG, anemia, PRU, left anterior descending coronary artery as the culprit vessel, multivessel disease, moderate or severe coronary calcification, total stent length, dialysis treatment, peripheral arterial disease, chronic heart failure, hypertension, previous PCI, body mass index, and enrollment at a site located in the United States versus outside United States All tests were 2 sided, and P<0.05 were considered statistically significant. Statistical analyses were performed with SAS version 9.4 (SAS Institute, Cary, NC).
Results
Patient Characteristics
Among the 8582 patients included in the ADAPT-DES study, 12 167 lesions underwent DES implantation, of whom 527 (4.3%) were located in a graft vessel, with 489 (4.0%) located in an SVG, 25 (0.2%) in an internal mammary artery graft, 2 (0.02%) in a radial artery graft, and 4 in an unspecified graft type (0.03%). On a patient level, 427 (5.0%) patients had PCI of a lesion within a graft vessel, 405 (4.7%) within an SVG, 23 (0.3%) within an internal mammary artery graft, 1 (0.01%) within a radial graft, and 3 (0.03%) patients within an unspecified graft type. Four of the patients who had PCI of an internal mammary graft and 1 of the patient who had PCI of a lesion in an unspecified graft also had PCI of a lesion located in an SVG.
WHAT IS KNOWN
• The failure of SVG requiring reintervention is relatively common and involves pathophysiologic mechanisms distinct from native coronary artery disease.
• Residual platelet reactivity among patients treated with clopidogrel is associated with increased risk of adverse events after PCI.
WHAT THE STUDY ADDS
• Patients who underwent SVG PCI using DESs had considerably increased adjusted risk of adverse ischemic events compared with patients undergoing PCI of native coronary arteries.
• Residual platelet reactivity seems to increase the risk of adverse events to a similar degree for patients undergoing SVG and native coronary PCI.
• These data suggest that better strategies to manage SVG failure are needed, including alternative revascularization strategies and enhanced pharmacotherapy. Compared with patients who had PCI of non-SVG vessels, patients who had PCI of a lesion in an SVG were on average older and were more likely to be men. They also had more cardiovascular risk factors but were less likely to smoke. Patients who had PCI of an SVG more often had multivessel coronary artery disease (Table 1) . They were also more likely to have HPR (Table 1 ; Figure I in the Data Supplement). After multivariable adjustment, no association between SVG PCI and PRU (adjusted difference, 0.89 U; 95% confidence interval, −8.55 to 10.32; P=0.85) was found. Angiographically, patients who underwent PCI of an SVG were less likely to have calcified lesions or a chronic total occlusion (index PCI lesion) compared with patients with PCI of a native coronary artery (Table 1) . Patients who had PCI of an SVG were more likely to be on dual antiplatelet therapy at 1 year and 2 years post-PCI. They were also more likely to use warfarin (Table II in Figure 1 ; Table 2 ). Bleeding risk was similar between the 2 groups. When compared with the subset of non-SVG PCI patients who had previous CABG SVG PCI was still associated with considerably higher crude rates of adverse ischemic events but similar bleeding rate (Figure 2 ; Figure II in the Data Supplement). After multivariable adjustment, the risk of ischemic events remained significantly higher after PCI of an SVG than after PCI of a non-SVG lesion, whereas the adjusted risk of bleeding remained similar in both groups (Figure 3 ). Results were consistent in sensitivity models that excluded patients without previous CABG (Table 3; Table III in the Data Supplement). After propensity score matching, the groups were well balanced (Table IV in the Data Supplement). There was no statistical interaction between platelet reactivity and SVG PCI versus non-SVG PCI in regard to the risk of 2-year ischemic or bleeding events (Figure 4 ; Figure III in the Data Supplement). Similarly, the effect of SVG PCI versus non-SVG PCI on 2-year major adverse cardiac events risk was similar regardless of the patient presented with stable coronary artery disease (hazard ratio, 2.54; 95% confidence interval, 1.65-3.92) or acute coronary syndromes (hazard ratio, 2.11; 95% confidence interval, 1.42-3.13; P interaction =0.47).
Discussion
The present study is the first to address the association between SVG PCI, platelet reactivity, and outcomes after successful PCI. Our main findings are that with follow-up through 2 years after successful PCI: (1) SVG PCI compared with non-SVG PCI was associated with an approximate 3-fold increased unadjusted and a 2-fold increased adjusted risk of ischemic events; (2) the effect of HPR on ischemic risk seems to be similar in SVG and non-SVG PCI; and (3) the increased risk of ischemic events with SVG PCI versus non-SVG PCI was not paralleled by a similar increase in the risk of bleeding.
In ADAPT-DES, SVG PCI represented >95% of reinterventions of failed surgical conduits, with a minority of interventions performed for arterial graft failure such as the mammary artery. This observation is consistent with previous studies and is reflects the considerably worse long-term patency with venous conduits compared with arterial grafts. [11] [12] [13] [14] [15] [16] [17] [18] The high rate of reintervention within SVGs is thought to be related to an accelerated pattern of degeneration of the SVG conduit, with increased inflammation and thrombus formation contributing to graft failure. 2, 3 The higher rate of MI with SVG PCI compared with non-SVG PCI in our study, as well as in other reports, supports a potential role of thrombosis in the pathogenesis of SVG failure. 5, 6, 16, 19 However, reduced flow rate, altered shear stress, pronounced neointimal proliferation, and differential plaque and vessel (ie, absence of media) structure and composition are also likely to contribute to SVG failure. 4 Given the different pathophysiology of SVGs compared with native coronary arteries, we postulated that HPR may differentially affect the risk of adverse events after SVG PCI Values are % (n). compared with non-SVG PCI. However, we found that the risks of ischemic events associated with HPR were similar after SVG and non-SVG PCI, with no evidence of a statistical interaction. Despite the absence of an independent association between SVG PCI and PRU, PRU was higher among patients who had SVG PCI than among patients who had non-SVG PCI, likely contributing to the considerably increased risk of adverse events after SVG PCI. These observations also suggest that adherence to more potent and longer DAPT after SVG PCI may improve outcomes after SVG PCI. Consistent with this hypothesis, longer term DAPT has recently been shown to be more effective after PCI of complex lesions than after PCI of simple lesions. 20 Conversely, the responses to pharmacotherapies in venous conduits may vary from native coronary arteries, and one could speculate whether anticoagulation rather than antiplatelet therapy would be more effective in preventing ischemic events after SVG PCI, at least during the early phase (≈6-12 months) post-implantation. 21 Notably, the observation that bleeding risk was similar for subjects who had SVG PCI and subjects who had non-SVG PCI in this study suggests that the risk-benefit tradeoff may favor more intense antiplatelet therapy after SVG PCI. In fact, subjects who had SVG PCI had similar bleeding risk as subjects who had non-SVG PCI despite being more likely to receive DAPT and being more likely to be on chronic oral anticoagulation. Even though patients with SVG lesions are typically older and are more likely to have comorbidities that increase bleeding risk, our data imply that the risk of ischemic events clearly exceeds the bleeding risk among subjects who have SVG PCI and who are treated with DAPT. 22 Nonetheless, the potential implications from these observations should all be considered hypothesis generating and require randomized trials for validation.
Limitations
This study has several limitations. First, as a post hoc analysis, our findings should be considered hypothesis generating. Second, the ADAPT-DES population received clopidogrel as the P2Y12 inhibitor. Newer P2Y12 inhibitors would be expected to reduce HPR after SVG PCI; the effect this would have on SVG PCI outcomes remains to be established. Third, ADAPT-DES included only patients who had successful PCI. Because SVG PCI is associated with a higher risk of procedural complications, including slow flow and no reflow, it is possible that the effect of HPR would have been more pronounced if patients who had unsuccessful PCI were also included. 23 We did not have data on the use of embolic protection devices, which are commonly used in SVG PCI. Event rates were low for some of the studied outcomes, including stent thrombosis; however, the main results were consistent across several sensitivity analyses. Finally, we did not have information on the age of the SVG. Therefore, we could not assess the association between PRU, SVG age, and outcomes.
In conclusion, compared with PCI in non-SVGs, PCI of diseased SVGs is associated with a considerably higher risk of adverse ischemic events at 2 years. HPR further increases the risk of long-term adverse events after PCI of both SVGs and non-SVGs to a comparable degree. Bleeding risk may not be increased to the same extent as ischemic risk after SVG PCI, suggesting that intensified antiplatelet therapy may be beneficial for these patients. Further studies are required to determine how to Multivariable Cox proportional hazards model adjusted for age, sex, diabetes mellitus, current smoking, renal insufficiency, clinical presentation, previous myocardial infarction, previous coronary artery bypass grafting, anemia, P2Y12 reaction units, left anterior descending coronary artery as the culprit vessel, multivessel disease, moderate or severe coronary calcification, and total stent length. The propensity scores were calculated using the following covariates: age, sex, diabetes mellitus, current smoking, renal insufficiency, clinical presentation, previous myocardial infarction, previous coronary artery bypass grafting, anemia, P2Y12 reaction units, left anterior descending coronary artery as the culprit vessel, multivessel disease, moderate or severe coronary calcification, total stent length, dialysis treatment, peripheral arterial disease, chronic heart failure, hypertension, previous percutaneous coronary intervention, body mass index, and enrollment at a site located in the United States versus outside United States. CI indicates confidence interval; and HR, hazard ratio.
*Patients who underwent saphenous vein graft percutaneous coronary intervention were matched 1:1 (388:388) to patients who underwent nonsaphenous vein grafts percutaneous coronary intervention, using a greedy matching algorithm and a caliper of 0.10. The risk of adverse cardiac events associated with SVG PCI compared with non-SVG PCI was similar regardless of whether the patient had high or low platelet reactivity. CI indicates confidence interval; HR, hazard ratio; and TVR, target vessel revascularization.
